1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4): iv1-iv86.
2. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stemcell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7(10)7: 813-20.
3. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2011; 29(11): 1400–7.
4. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of umors of the entral nervous system: a summary. Acta Neuropathol. 2016; 131(6): 803-20.
5. Packer RJ, Siegel KR, Sutton LN, Litmann P, Bruce DA, Schut L, et al. Leptomeningeal dissemination of primary central nervous system tumors of childhood. Ann Neurol 1985; 18(2):217-21.
6. Soares BP, Poretti A, Huisman TAGM. Magnetic resonance imaging to diagnose leptomeningeal spread of medulloblastoma in children: decreasing diagnostic uncertainty, moving in new directions. Pediatr Blood Cancer. 2017; 64(8): e26514.
7. Pang J, Banerjee A, Tihan T. The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms. J Neurooncol. 2008(1); 87:97-102.
8. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016; 278(2):563-77.
9. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4): 441-6.
10. Kim Y, Cho HH, Kim ST, Park H, Nam D, Kong DS. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI. Neuroradiology. 2018; 60(12): 1297-1305.
11. Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, et al. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology.2016; 281(3): 947-57.
12. Liu H, Zhang C, Wang L, Luo R, Li J, Zheng H, et al. MRI radiomics analysis for predicting preoperative synchronous distant metastasis in patients with rectal cancer. Eur Radiol. 2019; 29(8):4418-26.
13. Pang J, Banerjee A, Tihan T. The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms. J Neurooncol. 2008; 87(1):97-102.
14. Terterov S, Krieger MD, Bowen I, McComb JG. Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas. J Neurosurg Pediatr. 2010; 6(2): 131-6.
15. Miralbell R, Bieri S, Huguenin P, Feldges A, Morin AM, Garcia E, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group. Ann Oncol. 1999; 10(2): 239–41.
16. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol 2016.34(18):2157–64.
17. Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol. 2019; 21(3): 404-14.
18. Su C, Jiang J, Zhang S , Shi J, Xu K, Shen N, et al. Radiomics based on multicontrast MRI can precisely differentiate among glioma subtypes and predict tumour-proliferative behaviour. Eur Radiol. 2019; 29(4): 1986-96.
19. Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, et al. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol. 2017; 27(8):3509-22.
20. Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P. Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. Eur Radiol. 2017; 27(10):4188-97.
21. Rodriguez Gutierrez D, Awwad A, Meijer L , Meijer L, Manita M, Jaspan T, et al. Metrics and textural features of MRI diffusion to improve classification of pediatric posterior fossa tumors. AJNR Am J Neuroradiol. 2014; 35(5):1009-15.
22. Iv M, Zhou M, Shpanskaya K , Perreault S, Wang Z, Tranvinh E, et al. MR Imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2019; 40(1):154-61.
23. Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016; 131(6): 821-31.
24. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. MRI Surrogates for Molecular Subgroups of Medulloblastoma. AJNR Am J Neuroradiol. 2014; 35(7): 1263-9.
25. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol .2012;123(4):473-84.
26. Ding JL, Xing ZY, Jiang ZX, Chen J, Pan L, Qiu JG, et al. CT-based radiomic model predicts high grade of clear cell renal cell carcinoma. Eur J Radiol. 2018; 103:51–6.